News & Events
News
View All NewsSeptember 9th, 2021
ImmunoPrecise Reports Financial Results and Recent Business Highlights for First Quarter Fiscal Year 2022
VICTORIA, BRITISH COLUMBIA September 9, 2021 / – IMMUNOPRECISE ANTIBODIES LTD. (the “Company” or “IPA”) (NASDAQ: IPA) (TSX VENTURE: IPA), a leader in full-service therapeutic antibody discovery and development,…
September 8th, 2021
ImmunoPrecise’s Dutch Subsidiary Receives French Research Tax Credit (CIR) Accreditation
VICTORIA, BRITISH COLUMBIA September 8, 2021 / – IMMUNOPRECISE ANTIBODIES LTD. (the “Company” or “IPA”) (NASDAQ: IPA) (TSX VENTURE: IPA) a leader in full-service, therapeutic antibody discovery and development,…
September 7th, 2021
ImmunoPrecise Announces Participation at the H.C. Wainwright 23rd Annual Global Investment Conference on September 13-15, 2021 (Virtual Conference)
VICTORIA, September 7, 2021 / – IMMUNOPRECISE ANTIBODIES LTD. (the “Company” or “IPA”) (NASDAQ: IPA) (TSX VENTURE: IPA), a leader in full-service, therapeutic antibody discovery and development, today announced…
